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Abstract
Background: The use of drug combinations, including non-artemisinin-based and artemisinin-based combination
therapy (ACT), is a novel strategy that enhances therapeutic efficacy and delays the emergence of multidrug-
resistant Plasmodium falciparum. Its use is strongly recommended in most sub-Saharan African countries, namely
Cameroon, where resistance to chloroquine is widespread and antifolate resistance is emerging.
Methods: Studies were conducted in Cameroonian children with acute uncomplicated P. falciparum malaria
according to the standard World Health Organization protocol at four sentinel sites between 2003 and 2007. A
total of 1,401 children were enrolled, of whom 1,337 were assigned to randomized studies and 64 were included
in a single non-randomized study. The proportions of adequate clinical and parasitological response (PCR-
uncorrected on day 14 and PCR-corrected on day 28) were the primary endpoints to evaluate treatment efficacy
on day 14 and day 28. The relative effectiveness of drug combinations was compared by a multi-treatment
Bayesian random-effect meta-analysis.
Findings: The results based on the meta-analysis suggested that artesunate-amodiaquine (AS-AQ) is as effective as
other drugs (artesunate-sulphadoxine-pyrimethamine [AS-SP], artesunate-chlorproguanil-dapsone [AS-CD],
artesunate-mefloquine [AS-MQ], dihydroartemisinin-piperaquine [DH-PP], artemether-lumefantrine [AM-LM],
amodiaquine, and amodiaquine-sulphadoxine-pyrimethamine [AQ-SP]). AM-LM appeared to be the most effective
with no treatment failure due to recrudescence, closely followed by DH-PP.
Conclusion: Although AM-LM requires six doses, rather than three doses for other artemisinin-based combinations,
it has potential advantages over other forms of ACT. Further studies are needed to evaluate the clinical efficacy
and tolerance of these combinations in different epidemiological context.
Background
Chloroquine-resistant Plasmodium falciparum is now
widespread in Africa, and antifolate-resistant P. falci-
parum is emerging in some regions in Africa [1]. In
Cameroon, chloroquine is not effective, and its importa-
tion into the country has been officially stopped in
2002. Amodiaquine and sulphadoxine-pyrimethamine
were recommended for the first- and second-line
treatment of P. falciparum infections, respectively,
between 2002 and 2004.
To overcome drug-resistant malaria, malaria experts
advocate the use of combination therapy [2,3]. The most
commonly recommended combinations for Africa
include non-artemisinin-based combinations, such as
amodiaquine-sulphadoxine-pyrimethamine (AQ-SP), and
artemisinin-based combinations, such as artesunate-
amodiaquine (AS-AQ), artesunate-sulphadoxine-pyri-
methamine (AS-SP), and artemether-lumefantrine (AM-
LM). Other forms of artemisinin-based combinations
include artesunate-mefloquine (AS-MQ), dihydroartemi-
sinin-piperaquine (DH-PP), artesunate-chlorproguanil-
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nate-atovaquone-proguanil.
Cameroonian health authorities recommend AS-AQ
for the treatment of uncomplicated malaria since
2004. AM-LM is an alternative therapy in Cameroon
s i n c e2 0 0 6 .I nt h ep r e v i o u ss t u d i e s ,t h er e s u l t so ft h e
nationwide evaluation of the current therapeutic effi-
cacy of monotherapies (chloroquine, amodiaquine, and
sulphadoxine-pyrimethamine) were presented [4]. As
part of the national surveillance programme of drug-
resistant malaria and follow-up studies on combina-
tion therapies initiated in 2001, the present series of
subtrials presents the current efficacy of AQ-SP, AS-
A Q ,A S - S P ,A S - M Q ,A M - L M ,A S - C D ,a n dD H - P P
[5]. The aim of this series of subtrials was to consti-
tute a database of anti-malarial drug efficacy. These
findings provide a rational basis to consolidate the
on-going implementation of ACT throughout the
c o u n t r ya n dp r o v i d eb a s e l i n ed a t af o rp o s s i b l ea d j u s t -
ment and modifications in the national anti-malarial
drug policy in the future.
Methods
Patients
Clinical studies were conducted at four different urban
centres situated in different geographic area in Camer-
oon. Malaria transmission is intense and continuous
throughout the year in the country, except for the
northern (Garoua) and far-northern provinces (Maroua),
where transmission is low and seasonal. Children were
enrolled after free and informed consent of the parents
and/or legal guardians if the following inclusion criteria
were met: age ≤ five years of age, fever at the time of
consultation, parasite density ≥ 2,000 asexual P. falci-
parum parasites/μL of blood, without other Plasmodium
species [6]. As recommended by the standardized World
Health Organization (WHO) protocol for areas of low
transmission, the inclusion criteria were extended to
children up to nine years of age in Garoua and children
of all ages and adults in Maroua. Patients with symp-
toms associated with concomitant infectious diseases,
severe malnutrition, or any danger signs as defined by
the WHO were excluded. Study arms were calibrated
based on WHO criteria [6]. Each substudy was an open-
label trial using drugs both commonly available and
commonly used in the selected health care centres. The
studies were approved by the Cameroonian National
Ethics Committee and the Cameroonian Ministry of
Public Health before the initiation of the first campaign
in 1995 and amended in 1997 (Number UYI/FMSB/
DEPT/HEMAT/L.No 35/95). The study protocol was
initiated in 2003 and extended up to 2007, with yearly
campaigns.
Treatment and follow-up
Patients were randomized to two or three treatment
groups, with the exception of the study conducted in
Maroua where only AS-AQ combination was evaluated.
Separate concealed-random list based on random num-
ber tables was prepared for each trial by the principal
investigator. Patients were consecutively allocated by the
local investigator according to the corresponding list.
Amodiaquine (AQ) was administered at a standard dose
of 10 mg base/kg body weight on days 0, 1, and 2. Sul-
phadoxine-pyrimethamine (SP; 25 mg/kg body weight
sulphadoxine and 1.25 mg/kg body weight pyrimetha-
mine) was administered in a single dose. The dosage of
AQ-SP was the same as that of monotherapies. The first
doses of AQ and SP were administered simultaneously
on day 0, followed by AQ alone on days 1 and 2.
AS was administered at a total dose of 12 mg/kg body
weight (4 mg/kg body weight on days 0, 1, and 2) for all
ACTs containing AS. The following dosages of ACT
were administered: AS-AQ (AS, 4 mg/kg/day and AQ,
10 mg/kg/day) on days 0, 1, and 2; AS-SP, (SP on day
0); AS-MQ (MQ, 15 mg/kg on day 1 and 10 mg/kg on
day 2); and DH-PP (Duo-Cotecxin®) 6.4 mg/kg body
weight of DH and 51.2 mg/kg body weight of pipera-
quine in 3 divided daily doses. Six doses of AM-LM
(Coartem®) were administered as recommended by the
manufacturer. For the AS-CD combination, the dose of
chlorproguanil-dapsone (Lapdap®) was given once daily
for three days, as recommended by the manufacturer.
Paracetamol (30 mg/kg body weight/day) was adminis-
tered to all patients.
Patients included in the respective AQ, SP, AQ-SP
arms of the 2003-subtrial were followed on days 1, 2, 3,
7, and 14, as recommended by the 1996 WHO protocol
[7]. All patients included in the subtrials after 2003 were
followed on days 1, 2, 3, 7, 14, 21, and 28 (also day 42
for patients assigned to AS-MQ group), as recom-
mended in the WHO protocol modified in 2003 [6].
Haematocrit measurement was repeated on day 14.
Each dose of anti-malarial drugs was administered
under supervision during the visits. Patients who failed
to respond to the assigned drug were treated with oral
quinine (25 mg/kg body weight/day for 5 days), artesu-
nate-amodiaquine, or artemether-lumefantrine. The pri-
mary outcome was an adequate clinical and
parasitological response (ACPR) on day 28 [6]. For com-
parison, ACPR on day 14 was also considered.
Polymerase chain reaction (PCR)
Fingerprick capillary blood was collected for blood
smear and DNA analysis at the time of treatment or
parasitological failure occurring on day 7 or after. The
polymorphic merozoite surface antigen-1 (msa-1),
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protein (glurp) genes of the pre-treatment and recrudes-
cent samples were amplified, as recommended by a
group of malaria experts [8]. PCR products of pre-treat-
ment and post-treatment samples were analysed by
agarose gel electrophoresis.
Statistical analyses
Both intention-to-treat and per protocol analyses on the
percentage of ACPR on day 14 and 28 were performed.
Proportions of late failure occurring after day 14 were
corrected for re-infection by comparing the PCR pro-
ducts of pre-treatment and post-treatment isolates. The
calculations were based on both PCR-uncorrected and
PCR-corrected proportions of ACPR for the 28-day
studies.
For the 14-day follow-up study (in 2003), significant
difference between AQ, SP, AQ-SP arms was tested
using ANOVA for the binary variable ACPR 1/treatment
failure 0. The test of the efficacy trend of AQ-SP
between 2003 and 2006 was performed by comparing
the rate of ACPR in 2003 to the rate in 2006 using the
odds ratio (OR) on day 14.
For each 28-day follow-up study (2005-2007), the ORs
and 95% confidence intervals were calculated. The
Yusuf and Peto method was used for the 2006-study
(AS-AQ versus AM-LM) as the AM-LM arm showed
100% ACPR patients after PCR adjustment [9]. On days
2, 3, 14 and 28, we used a logistic regression model to
compare other forms of ACT, with AQ-SP as the refer-
ence treatment. Time to parasite clearance was com-
pared using the log-rank test.
Unlike the classical random-effect meta-analysis,
where there is the same reference treatment or placebo
across the trials, a pooled effect and summary OR versus
a reference treatment could not be directly estimated
s i n c et r e a t m e n t sw e r en o tt h es a m ef r o mo n es t u d yt o
the other [10]. As the same treatment was repeatedly
found in some of the arms among the different trials, a
general Bayesian model referred to as a multi-treatment
random-effect meta-analysis was used, taking into
account the heterogeneity between studies and regroup-
ing these data to compare treatments. The model used
was an extension of the one proposed for individual
patient data [11].
The treatment response per subject was viewed as a
binary variable, i.e. 1 for ACPR and 0 for failure. Data
were agglomerated on day 14 for all studies, and on day
28 based on both PCR- uncorrected and corrected
results when the follow-up reached 28 days or more.
The model estimated i) posterior OR for each treatment
compared to the AS-AQ treatment, ii) the variability
among subjects within sub-trials and iii) the variability
among treatment groups, starting with reasonable prior
distribution for each parameter.
Data were analysed using the statistical software R
[12]. For the Bayesian random-effect meta-analysis, the
WinBugs14 software was used [13].
Results
Study population
A total of 1,401 patients were enrolled in our series of
studies (1,337 in randomized studies and 64 in a single
non-randomized AS-AQ study in Maroua). All analysed
data are presented in a CONSORT format in Fig. 1[14].
Patients included in 2003 (n = 542) were followed up
until day 14. Patients included in 2005-2007 (n = 859)
were followed up until day 28 (until day 42 for AS-
MQ). The clinical and parasitological characteristics are
presented in Additional File 1. In 2003, 519 patients
completed the visit on day 14, and 23 (4.2%) were either
lost to follow-up or excluded. In the 28-day trial, 734
patients completed the visits on day 28; and 61 (7.6%)
were either lost to follow-up or excluded. The overall
mean haematocrit increased from 18.5 ± 1.7% on day 0
to 31.3 ± 5.6% on day 14, i.e. by 12.8% (95% CI, 11.2-
14.4%; P < 0.05). Even among patients with relatively
high initial parasitaemia (> 200,000 asexual parasites/μL
of blood; n = 32), the mean pre-treatment haematocrit
(28.5 ± 5.4%) increased to 34.6 ± 4.0% on day 14, i.e.
increase by 6.2% (95% CI, 4.3-8.0%; P < 0.05), attesting
the general benefit of an effective combination therapy.
Efficacy of AQ, SP, AQ-SP
With the AQ-SP treatment, the overall cure rate, i.e.
ACPR, was 93.0% on day 14 and 78% on day 28 before
PCR correction and 91% after PCR correction (Figure
2). There was no indication of change in the efficacy of
AQ monotherapy between 2003 and 2005 (OR = 1.61,
95% CI 0.6-4.54) on day 14. SP was less effective than
AQ-SP (OR = 0.33; 95% CI, 0.14-0.77; P =0 . 0 1 ) ,w i t h
an overall cure rate of 87% (95% CI, 0.82-0.92) on day
14. In 2003, the efficacy of AQ-SP was not statistically
different from AQ monotherapy (P >0 . 0 5 ) .T h e r ew a s
no significant difference in the efficacy of AQ-SP
between 2003 (145/156 or 93%) and 2006 (64/67 or
96%) on day 14 (OR = 0.62; 95% CI, 0.16-2.3).
Efficacy within the 28-day trial
From 2005 to 2007, the efficacy of artemisinin deriva-
tives combined with a partner drug was assessed on day
28. The treatment outcomes of combination therapies,
before and after PCR adjustment of the number of
ACPR, are summarized in Tables 1 and 2. In 2005, for
AQ, AS-AQ and AS-SP, based on the intention-to-treat
(ITT) analysis, the rates of success were, for the
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tively and after PCR correction, 86%, 88.3% and 88.5%,
respectively. There was no significant difference among
the 3 treatments. Between AS-AQ and AM-LM, the suc-
cess rate based on the PCR-uncorrected proportions of
ACPR on day 28 was not significantly different (ITT:
OR = 0.26; 95% CI, 0.07-1.03). After PCR correction,
t h e2 8 - d a yc u r er a t e sw e r e8 8 . 7 %a n d9 8 . 3 %f o rA S - A Q
and AM-LM, respectively (ITT: OR = 0.13; 95% CI,
0.01-1.10). Moreover, the time to obtain parasitological
clearance was similar in the two groups (P =0 . 1 3 ) .A S -
AQ combination was less effective (PCR-uncorrected
ACPR, 79.3%) than DH-PP (PCR-uncorrected ACPR,
92.3%) (ITT OR = 0.32; 95% CI, 0.12-0.80; per protocol
[PP] OR = 0.12; 95% CI, 0.02-0.52). After PCR adjust-
ment, the cure rates on day 28 were 92.7% and 88.0%
for DH-PP and AS-AQ, respectively (ITT OR = 0.61;
95% CI, 0.22-1.66). Parasite clearance time was longer
with DH-PP than AS-AQ (P < 0.05). Based on the ITT
analysis, the AS-CD combination was less effective
(PCR-uncorrected ACPR, 63.8%) than AS-SP (PCR-
uncorrected ACPR, 85.9%) (OR = 0.30; 95% CI, 0.13-
0.62). After PCR adjustment, the cure rates on day 28
were 91.7% and 76% for AS-SP and AS-CD, respectively
(OR = 0.40; 95% CI, 0.17-0.85).
Based on the PCR-corrected proportions of ACPR on
day 28, there was no statistical difference in the efficacy
of AQ-SP and AS-MQ combinations (ITT: 92.5%
Figure 1 CONSORT flow diagram. ** The number of includedpatient in the corresponding treatment group. *The number of observedACPR
without PCR correction. § The number of ACPR corrected by PCR. §+: The total number of patient followed (number of observed ACPR +
number of failures). The number of patient either lost to follow-up or excluded is obtained by subtracting §+ from **. §++ a non randomized
study of AS-AQ.
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The decrease in parasitaemia was more rapid with AS-
MQ than AQ-SP on day 2 (OR = 10.0, 95% CI, 4.2-23.6,
P < 0.05). However, on day 3 (see Table 1), the propor-
tions of parasite clearance were similar (95.7% vs 86.6%;
P = 0.13). Moreover, more than 90% of patients cleared
their parasitaemia on day 3, except for the AQ-SP com-
bination and AQ monotherapy.
Treatment failure occurred in one out of 61 patients
(1.7%, PCR-uncorrected LPF) treated with AS-MQ on
day 28. Failure was observed in five additional patients
(one LPF and four LCF, PCR-uncorrected; one lost-to-
follow-up) between day 29 and day 42. Vomiting in chil-
dren treated with AS-MQ occurred more frequently
than in the AQ-SP group, on day 1 (10.3% vs 1.5%), day
2 (10.8% vs 0) and day 3 (3.3% vs 1.6). Significant differ-
ence was observed on day 1 and 2 (P < 0.05). Three
patients were excluded due to repeated vomiting asso-
ciated with AS-MQ administration.
Regression analyses
The logistic regression on pooled individual patient data
(PCR-uncorrected) comparing the efficacy of ACT to
that of AQ-SP showed that the efficacy of AQ-SP is not
Figure 2 Comparison of the efficacy of AQ monotherapy, SP monotherapy, and AQ-SP combination in 3 sites during the 14-day
follow-up period in 2003. Individual success rates (PCR uncorrected) are plotted. The horizontal line represents 95% confidence interval (CI) of
each estimated proportion p, which is based on asymptotic normality. Black squares on each line denote the estimated proportion of adequate
clinical and parasitological response (ACPR). The first dotted vertical line to the left corresponds to 75% of ACPR under which the treatment is
considered as ineffective. The last 3 rows and their corresponding vertical lines refer to the global effect observed for sulphadoxine-
pyrimethamine (SP; 88% ACPR), amodiaquine (AQ; 93% ACPR), and amodiaquine-sulphadoxine-pyrimethamine (AQ-SP; 94% ACPR), respectively.
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SP, and DH-PP on day 14 (Table 3). However, the effi-
cacy of AS-CD was significantly lower (P < 0.05) than
that of AQ-SP, at both endpoints on day 14 and day 28.
AM-LM and DH-PP were significantly more effective
than AQ-SP on day 28.
Multi-treatment random-effects meta-analysis
The results of the multi-treatment Bayesian random-
effects meta-analysis based on individual data of chil-
dren are shown in Figure 3. Posterior OR for each treat-
ment was plotted. There was no significant difference in
efficacy between AS-AQ and AM-LM: day 14 OR =
1.33 (95% CI, 0.62-2.88); day 28 PCR-uncorrected OR =
2.04 (0.76-5.47); day 28 PCR-corrected OR = 1.84 (0.73-
4.66). The same conclusion holds for AS-CD, AS-MQ,
AQ-SP, DH-PP, AS-SP, and AQ, on day 14 and on day
28, before and after PCR correction.
Discussion
The present work concerned a global analysis of a series
of randomized studies of anti-malarial treatment efficacy
conducted in Cameroon between 2003 and 2007. Fol-
lowing comparison between arms within each study, a
multi-treatment Bayesian random-effects meta-analysis
of the binary outcome, ACPR/failure as a marker of effi-
cacy, was carried out both on day 14 and day 28. The
latter used PCR-uncorrected and PCR-corrected data.
This global approach increased the power for detecting
differences between treatments, while controlling the
type-1 error.
Anti-malarials were AQ and SP monotherapies, their
combination AQ-SP, and new drugs included in ACT. AQ
monotherapy is still effective in Cameroon but should be
protected with artesunate (or SP) to delay the emergence
of resistance. The current trend in Africa is to reserve SP
for the intermittent preventive treatment in pregnant
women [15]. During the transition period before the actual
implementation of the new drug policy based on ACT,
AQ-SP combination has been proposed by some malaria
experts to be an effective, alternative non-ACT combina-
tion [3]. The results showed that AQ-SP combination was
more effective than AQ and SP monotherapies, in agree-
ment with our earlier randomized study performed at
another sentinel site and studies conducted elsewhere in
Africa and Asia [5,16]. AQ-SP was as effective as AS-AQ
combination, as already shown in a meta-analysis in Africa
[17]. The advantages of AQ-SP combination include its
Table 1 Distribution of the responses in the 28-day trial
Year Treatment Number
included
Parasite clearance on day 3
(ITT) (%)
Observed
ACPR
Lost to follow-up and
excluded
Reinfection ITT
1 PP
1
2005 AQ 64 87.5 50 5 5 50/64
(55/64)
50/59
(55/59)
AS-AQ 60 100 43 6 10 43/60
(53/60)
43/54
(53/54)
AS-SP 61 96.8 50 4 4 50/61
(54/61)
50/57
(54/57)
2006a AQ-SP 67 86.6 55 5 7 55/67
(62/67)
55/62
(62/62)
AS-MQ 69 95.7 60 8 1 60/69
(61/69)
60/61
(61/61)
2006b AS-AQ 62 98.4 52 5 3 52/62
(55/62)
52/57
(55/57)
AM-LM 61 100 58 1 2 58/61
(60/61)
58/60
(60/60)
2006c AS-CD 83 97.6 53 12 7 53/83
(60/83)
53/71
(60/71)
AS-SP 85 100 73 6 1 73/85
(74/85)
73/79
(74/79)
2007 AS-AQ 92 99 73 4 8 73/92
(81/92)
73/88
(81/88)
DH-PP 91 100 84 5 0 84/91
(84/91)
84/86
(84/86)
1Values in parentheses denote the observed proportions of ACPR after PCR correction in each treatment group. No recrudescence was observed with the AM-LM
combination, and no re-infection was observed with DH-PP. ITT, intention-to-treat; PP, per protocol.
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immediate availability of both drugs in many areas in
Africa, and relatively low price of the generic drugs.
Therefore, this non-ACT would have been a useful alter-
native during the transition period towards the full imple-
mentation of ACT to mutually protect AQ and SP in
African countries where these two drugs are still effective.
In Cameroon, AS-AQ and AM-LM have being used
nationwide since 2007 although AM-LM is relatively
less prescribed due to its low supply in the public sector.
The present study indicates that AS-AQ is well-tolerated
and highly effective, confirming the results of an earlier
multicentric study conducted in Africa [18]. Current
concerns for the use of AS-AQ in Cameroon include
the high number of individual non-coformulated AS and
AQ tablets and the common perception that AQ intake
provokes excessive fatigue and, in some patients, pruri-
tus. The minor, transient side effects of AQ may lead to
poor compliance and subsequent decline in AQ efficacy.
T h er e s u l t so ft h ep r e s e n ts t u d yh i g h l i g h t e dan o n - s i g -
nificant difference between AM-LM and AS-AQ. AM-
LM is highly effective when the twice daily doses (total
of six doses) are administered under supervision. As in
the case of AS-AQ currently employed in Cameroon,
there are concerns that six doses of AM-LM over three
days may reduce compliance. Relatively few numbers of
patients complained of physical fatigue during AM-LM
treatment.
The forms of ACT, i.e.A S - S P ,A S - C D ,A S - M Q ,D H -
PP, that require once daily dose for three days, did not
show a significant difference with AS-AQ. Previous stu-
d i e sh a v es h o w nt h a tA S - S Pi sah i g h l ye f f e c t i v eA C T
[19]. However, in some African countries, this drug
combination is not recommendable due to an increasing
prevalence of antifolate resistance. The relatively higher
number of reinfections observed between day 14 and
day 28 in the AS-CD arms may partially be explained by
the shorter elimination half-life of CD, compared with
that of SP. Dapsone and chlorproguanil are antifolates
that share similar chemical structures as sulphadoxine
and pyrimethamine, respectively, and share the same
mode of action. Although CD has been shown to be
more effective than SP in several African countries, the
development of AS-CD will not be further pursued by
Table 2 Outcome of intent-to-treat and per-protocol analyses on day 28 with PCR distinction between recrudescence
and reinfection.
Comparator
1 Treatment PCR-uncorrected outcome PCR-corrected outcom
OR (ITT) OR (PP) OR (ITT) OR (PP)
AS-AQ AQ 0.71
(0.31-1.60)
0.70
(0.26-1.85)
1.24
(0.43-3.56)
3.85
(0.41-35.6)
AS-AQ AS-SP 0.60
(0.23-1.31)
0.55
(0.20-1.53)
0.98
(0.32-3.00)
2.94
(0.30-29.2)
AQ-SP AS-MQ 0.68
(0.26-1.75)
0.13
(0.01-1.10)
1.62
(0.50-5.24)
-
-
AS-AQ AM-LM 0.26
(0.07-1.03)
0.36
(0.06-1.92)
0.13
(0.01-1.10)
0.12
(0-2.04)
AS-CD AS-SP 0.30*
(0.13-0.62)
0.24*
(0.09-0.65)
0.39*
(0.17-0.85)
0.37
(0.12-1.20)
AS-AQ DH-PP 0.32*
(0.12-0.80)
0.12*
(0.02-0.52)
0.61
(0.22-1.66)
0.28
(0.05-1.36)
Treatment outcome on day 28 for studies conducted in 2005-2007. OR (ITT), odds ratio in the case of the intention-to-treat (ITT) analysis, where the total number
of patients enrolled was considered. OR (PP), odds ratio in the per-protocol (PP) analysis.
1Treatment taken as reference. Odds-ratios (OR, 95% confidence intervals in parentheses) were calculated for the pairs of ACT in each randomized study, except
for the study in 2005 (AS-AQ vs AQ). Asterisks denote P < 0.05.
Table 3 Comparison of pooled PCR-uncorrected
proportions of adequate clinical and parasitological
response between AQ-SP and ACT.
ACT Odds-ratio (95% CI), as compared to AQ-SP
day 2 day 3 day 14 day 28
AM-LM 25.6
(8.21-79.5)*
ND 2.81
(0.28-27.7)
6.32
(1.35-29.6)*
AS-AQ 26.4
(12.4-56.4)*
16.0
(3.35-76.1)*
0.72
(0.20-2.62)
0.80
(0.40-1.61)
AS-CD 34.7
(11.2-107)*
ND 0.26
(0.07-0.96)*
0.35
(0.16-0.75)*
AS-MQ 11.4
(4.76-27.1)*
3.26
(0.84-12.7)
0.36
(0.10-1.41)
1.45
(0.57-3.71)
AS-SP 18.9
(8.64-41.2)*
5.30
(1.57-17.9)*
0.91
(0.22-3.64)
1.34
(0.60-2.93)
DH-PP 37.4
(12.2-115)*
ND 0.80
(0.18-3.50)
9.16
(2.0-42.5)*
Patients who were excluded or lost-to-follow-up were not included in the
analysis. Data from a total of 709 patients were analysed, with treatment as a
single covariate. Asterisks denote P < 0.05. ND (not done) denotes infinite OR
due to 100% ACPR. On day 7, 100% ACPR was observed with all bitherapies.
ACT, artemisinin-based combination therapies; AS-AQ, artesunate-
amodiaquine; AS-MQ, artesunate-mefloquine; AS-SP, artesunate-sulphadoxine-
pyrimethamine; AM-LM, artemether-lumefantrine; AS-CD, artesunate-
chlorproguanil-dapsone; DH-PP, dihydroartemisinin-piperaquine; AQ-SP,
amodiaquine-sulphadoxine-pyrimethamine.
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matological adverse effectsa s s o c i a t e dw i t hd a p s o n e
[20-22].
AS-MQ combination has been widely used in some
Southeast Asian countries to treat multidrug-resistant P.
falciparum infections for more than a decade [23]. Its
efficacy remains very high in Asia although some recent
studies have suggested a possible decline in its efficacy
[24-26]. In many parts of Africa, MQ, alone or in com-
bination with SP, has rarely been used by the local
populations. Initial studies of AS-MQ combination con-
ducted in children aged > 5 years old and adults in
Africa suggested its high efficacy (98-100% cure rate)
and good tolerance [27,28]. The present study in
children less than five years of age confirms the high
efficacy of AS-MQ combination, although the corre-
sponding frequency of vomiting seems to be in contra-
diction with those of previous studies, which involved
sequential or simultaneous doses [27,29].
Piperaquine, an ‘old’ bisquinoline synthesized in the
1960s and used extensively in China, has been found to
be a suitable partner of dihydroartemisinin [30]. Recent
studies conducted in Asia have shown its high efficacy,
safety, and good tolerance [31-33]. The results of the pre-
sent study confirm its high efficacy and safety in malaria-
infected African children. DH-PP may be a low-cost,
effective alternative. Before piperaquine, in combination
with dihydroartemisinin, is introduced at the regional
level in Africa, its industrial production needs to conform
to Good Manufacturing Practice standard [30].
The results of these studies on the efficacy of AS-AQ
and AM-LM are in agreement with those conducted
elsewhere in Africa [1]. The various forms of ACT that
have not been extensively evaluated elsewhere, namely
AS-MQ and DH-PP, are probably just as effective in
other African countries. The choice of either AS-AQ or
AM-LM for the treatment of uncomplicated malaria has
led to some confusion among prescriptors, drug suppli-
ers, and patients themselves in Cameroon. For a more
rational drug distribution, an urgent measure is required
for a clearer anti-malarial drug policy, defining clinical
conditions in which alternative forms of ACT may be
prescribed. Other effective forms of ACT (AS-SP, AS-
C D ,A S - M Q ,D H - P P )m a yb em o r ep r o m i s i n gi nt e r m s
of compliance. The possible role of AS-SP in combating
drug-resistant P. falciparum in Central Africa is not well
d e f i n e da tp r e s e n t .I nc o u n t r i e sw h e r eS Pi sl a r g e l y
employed for intermittent preventive treatment in preg-
nant women, it may not be advisable to use AS-SP for
malaria treatment of the general population. Further
studies are required to evaluate the optimal dosing of
AS-MQ for African children. At present, it is probably
too early to recommend AS-MQ in Africa as an alterna-
tive to other existing forms of ACT, which are better
tolerated than AS-MQ. There are other novel forms of
ACT, including artesunate-pyronaridine and artesunate-
Figure 3 Random-effects meta-analysis of treatment efficacy. Posterior mean with 95% CI for odds ratios of each combination treatment
with respect to AS-AQ (dotted line) for ACPR on day 14, and day 28 PCR uncorrected and corrected. Intention-to-treat analysis with individual
patient data.
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Page 8 of 10atovaquone-proguanil, that have not been evaluated in
the present study. Clinical efficacy and tolerance of
these combinations need to be evaluated and compared
with those of AS-AQ and AM-LM in Central Africa.
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Additional file 1: Table S1: Pre-treatment clinical and laboratory
characteristics of enrolled children who completed the 14-day or
28-day follow-up.
1 Patients were followed-up for 14 days in studies
conducted in 2003 and for 28 days in studies performed in 2005-2007.
Patients assigned to artesunate-mefloquine group were followed for 42
days. AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; AS, artesunate;
MQ, mefloquine; AM, artemether; LM, lumefantrine; CD, chlorproguanil-
dapsone; DH, dihydroartemisinin; PP, piperaquine.
2 Number of patients
enrolled (number of patients analyzed, with complete 14- [in 2003] or
28-day [in 2005-2007] follow-up, in parentheses).
3 The numbers of
children aged > 60 months old (and/or adults for Maroua) are 18/57 in
Garoua 2003 AQ, 16/58 in Garoua 2003 SP, 27/58 in Garoua 2003 AQ-SP,
and 18/64 (28.1%) in Maroua (none at other study sites). Garoua and
Maroua are situated in northern Cameroon where malaria transmission is
seasonal.
4 The following number of patients had > 200,000 asexual
parasites/μL of blood: 2 (1 in AQ group and 1 in SP group) in Yaoundé
2003; 5 (2 in AQ group and 3 in SP group) in Bertoua 2003; 3 (2 in AQ
group and 1 in AQ-SP group) in Garoua 2003; 10 (5 in AQ group, 4 in
AS-AQ group, and 1 in AS-SP group) in Yaoundé 2005; 1 in Maroua; 4 (2
in AQ-SP group, 2 in AS-MQ group) in Yaoundé 2006a; 5 (4 in AS-AQ
group, and 1 in AM-LM group) in Yaoundé 2006b; 7 (5 in AS-SP group
and 2 in AS-CD group) in Yaoundé 2007a; and 11 (5 in DH-PP group and
6 in AS-AQ group) in Yaoundé 2007b.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-2875-9-56-
S1.DOC]
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